4.7 Article

Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 204, Issue 6, Pages 1475-1485

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20062694

Keywords

-

Funding

  1. NCI NIH HHS [CA94922, T32 CA060395, R01 CA094922, 2T32CA60395-11] Funding Source: Medline
  2. NCRR NIH HHS [C06 RR015428, C06 RR-15428-01] Funding Source: Medline
  3. NIAID NIH HHS [AI056094, R01 AI056094, AI064639, R01 AI057555, AI057555, R56 AI056094, R37 AI064639, R01 AI064639] Funding Source: Medline

Ask authors/readers for more resources

The deubiquitinating enzyme CYLD has recently been implicated in the regulation of signal transduction, but its physiological function and mechanism of action are still elusive. In this study, we show that CYLD plays a pivotal role in regulating T cell activation and homeostasis. T cells derived from Cyld knockout mice display a hyperresponsive phenotype and mediate the spontaneous development of intestinal inflammation. Interestingly, CYLD targets a ubiquitin- dependent kinase, transforming growth factor-beta-activated kinase 1 (Tak1), and inhibits its ubiquitination and autoactivation. Cyld-deficient T cells exhibit constitutively active Tak1 and its downstream kinases c-Jun N-terminal kinase and I kappa B kinase beta. These results emphasize a critical role for CYLD in preventing spontaneous activation of the Tak1 axis of T cell signaling and, thereby, maintaining normal T cell function.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available